Skip to main content
. 2021 Mar 23;13(6):1483. doi: 10.3390/cancers13061483

Figure 2.

Figure 2

Response to Abiraterone (AA) and Enzalutamide (E) of the wild-type PCa cell lines. Proliferation, cell cycle and quantification of AR, AR-V7, AR-V9 and AR target genes. PCa cells were treated for 5 days with 40 μM Enz, 20 μM AA or the combination (40 μM Enz + 20 μM AA). (A) Analysis of cell proliferation using xCELLigence. Results are normalized to untreated cells considering their final value after 5-day cultures 100%. Data shown correspond to the mean ± SD calculated from the quadruplicates made for each condition. (B) Cell cycle analysis after Enz, AA or the combination (E + AA) treatments for 5 days in LNCaP, 22RV1 and PC-3 cell lines. Stacked bar graphs show the percentages for each cell cycle phase; error bar corresponds to the SD calculated from the triplicates for each experimental condition. (C) qPCR analysis for AR isoforms and some of AR target genes after Enz, AA or the combination (E + AA) treatments for 5 days in LNCaP (left panels), 22RV1 (middle panels) and PC-3 (right panels). The results are shown after normalization with respect to endogenous control (GADPH) and referenced to the control group (wild-type untreated cells). The error bars correspond to the SD calculated from triplicates.